Overview Request Sample Pages Request Customization Download PDF
You are viewing: China Veterinary Biologics Market analysis
Part of: Veterinary Biologics Market (Global)

The China Veterinary Biologics Market was valued at $25.02 Million in 2025 and projected to reach to $34.06 Million by 2030, representing a compound annual growth rate of 6.4%. China's veterinary biologics market is poised for sustained growth through 2030, driven by modernization of animal agriculture and increasing biosecurity concerns.

China Veterinary Biologics Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China Veterinary Biologics Market Trends and Insights

  • This growth trajectory reflects China's increasing investment in animal health infrastructure and rising demand for advanced immunological products across livestock and companion animal segments.
  • China's market expansion is driven by regulatory modernization, growing aquaculture and poultry industries, and heightened biosecurity awareness following disease outbreaks. The 6.4% compound annual growth rate in China significantly outpaces the global average of 5.2%, positioning China as a high-growth market within the Asia Pacific region.
  • China's veterinary biologics sector benefits from government support for domestic vaccine manufacturing, expanding middle-class pet ownership, and intensified focus on food safety standards.
  • Between 2025 and 2030, China is expected to consolidate its position as a key production and consumption hub for veterinary biologics in Asia. China's market dynamics are shaped by both domestic consumption and export potential, with local manufacturers increasingly competing alongside international players.
  • The forecast period through 2030 will likely see China strengthen its regulatory framework and accelerate adoption of advanced biologics technologies across animal health applications..

Key Market Statistics

  • CAGR (2025-2030) 6.4% CAGR
  • Market Size, 2025 ~USD 25.02 Million
  • Forecast, 2030 ~USD 34.06 Million
  • Country China

China Veterinary Biologics Market Overview

Market Valuation Growth :

China's veterinary biologics market is valued at USD 25.02 million in 2025, with a projected CAGR of 6.4% through 2030, reaching USD 34.06 million. This outpaces the global CAGR of 5.2%, positioning China as a high-growth market in the Asia-Pacific region.

Regulatory Infrastructure Expansion :

China's strengthened regulatory framework for animal health products and increased government investment in veterinary infrastructure are accelerating market adoption. Enhanced approval pathways for biologics are facilitating faster product launches and market penetration.

Livestock & Companion Animal Demand :

Rising demand across both livestock and companion animal segments is driving market expansion. China's growing middle class and increased pet ownership, combined with large-scale livestock operations, create diverse revenue opportunities for veterinary biologics manufacturers.

Immunological Product Innovation :

Advanced immunological products are gaining traction in China's market as producers seek improved disease prevention and animal health outcomes. Investment in R&D and technology adoption is accelerating the development of next-generation biologics tailored to Chinese market needs.

China Veterinary Biologics Market Dynamics

  • Government initiatives promoting animal health standards and disease prevention are creating favorable conditions for market expansion.
  • The rising prevalence of zoonotic diseases and livestock production intensification are compelling stakeholders to adopt advanced biological solutions. The companion animal segment is emerging as a significant growth driver, supported by urbanization and rising pet healthcare spending among Chinese consumers.
  • Strategic partnerships between domestic and international manufacturers, coupled with regulatory harmonization efforts, will further accelerate market development.
  • China's position as a major global livestock producer ensures sustained demand for innovative veterinary biologics solutions..

Related Ecosystem

Animal Health

Top Technologies
  • Polymerase Chain Reaction (PCR) Tests
  • Porcine
  • Immunodiagnostics
  • Lateral Flow Assays
  • Microarrays
Top Companies
  • Zoetis Inc.
  • Patterson Companies, Inc.
  • Virbac
  • Elanco Animal Health Incorporated
  • BOEHRINGER INGELHEIM GMBH

    Key Takeaways

    • China's veterinary biologics market is valued at USD 25.02 million in 2025 and will grow to USD 34.06 million by 2030, representing a 6.4% CAGR.
    • China's growth rate of 6.4% exceeds the global CAGR of 5.2%, making China one of the fastest-growing markets in the veterinary biologics sector.
    • China's market expansion is fueled by government support for domestic vaccine manufacturing, rising pet ownership, and strengthened biosecurity regulations.
    • China's position as both a producer and consumer of veterinary biologics will drive competitive dynamics and technology adoption through 2030.

    Veterinary Biologics Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment CANINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 5.2% from 2025 to 2030
    Largest Segment INJECTABLE ROUTE OF ADMINISTRATION (Route Of Administration)
    Market Size Base Year (Billions) ~USD 2.72 (2025)
    Revenue Forecast (Billions) ~USD 3.51 (2030)
    Segments Covered Product Type, Animal Type, Type, Route Of Administration, Application, End User

    China Veterinary Biologics Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Product Type

    • Diagnostic Kits
    • Immunodmodulators & Immunostimulants
    • Immunoglobulins & Antitoxins
    • Immunomodulators & Immunostimulants
    • Immuoglobulins & Antitoxins
    • Monoclonal Anitbodies
    • Monoclonal Antibodies

    By Animal Type

    • Companion Animal
    • Companion Animals
    • Livestock Animal
    • Livestock Animals

    By Type

    • Bovine
    • Canine
    • Equine
    • Feline
    • Intramuscular Route Of Administration
    • Intravenous Route Of Administration
    • Other Injectable Route Of Administration
    • Porcine
    • Poultry
    • Small Ruminant
    • Subcutaneous Route Of Administration

    By Route Of Administration

    • Injectable Route Of Administration
    • Oral Route Of Administration
    • Other Routes Of Administration

    By Application

    • Dermatology
    • Diagnostic Testing
    • Diagnostic Tetsing
    • Infectious Disease Prevention
    • Oncology
    • Other Applications
    • Pain Management

    By End User

    • Other End Users
    • Veterinary Diagnostic Labs
    • Veterinary Hospitals & Clinics

    CHINA: VETERINARY BIOLOGICS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    OTHER END USERS2.572.632.712.792.882.993.13.233.6
    VETERINARY DIAGNOSTIC LABS15.315.8116.3817.0117.7118.4819.3620.294.4
    VETERINARY HOSPITALS & CLINICS50.1552.5955.2758.2661.5365.1869.2673.685.9
    TOTAL68.0271.0374.3578.0682.1286.6591.7297.195.5

    Target Audience

    • Veterinary Biologics Manufacturers : Manufacturers need China-specific market data to develop localized product strategies, identify distribution partnerships, and optimize manufacturing investments. Understanding market dynamics enables competitive positioning and revenue forecasting.
    • Pharmaceutical & Biotech Companies : Companies seeking to expand into China's animal health sector require detailed market intelligence on regulatory pathways, competitive landscape, and customer preferences. This data supports M&A decisions and organic growth planning.
    • Veterinary Distributors & Retailers : Distributors need insights into market trends, product demand patterns, and customer segments to optimize inventory management and sales strategies. China-specific data enables better supplier negotiations and market positioning.
    • Investment & Private Equity Firms : Investors evaluating opportunities in China's animal health sector require comprehensive market analysis, growth projections, and risk assessments. This intelligence supports portfolio decisions and valuation models for veterinary biologics companies.
    • Government & Regulatory Bodies : Chinese regulatory agencies and agricultural ministries use market data to inform policy development, biosecurity initiatives, and animal health standards. Market insights support evidence-based decision-making for veterinary industry governance.

    Key Companies in the China Veterinary Biologics Market

    CompanyHQOwnershipStrongest segments
    IDEXXUnited StatesPublic CompanyCompanion Animal Group (in-clinic diagnostics, reference labs, services, software),Water Quality Products,Livestock, Poultry and Dairy (including related diagnostics),
    ELANCOUnited StatesPublic CompanyCompanion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal),Companion animal vaccines and therapeutics (Galliprant, Atopica, Milbemax, Onsior, Tru Family),Farm animal feed additives and productivity enhancers (Rumensin, Experior, Hemicell, Surmax, Pulmotil),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations),Vaccines (Gardasil, pediatric and adult vaccines including Vaxneuvance, Capvaxive),Cardiovascular, pulmonary hypertension and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, others),
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    NEOGEN CORPORATIONUnited StatesPublic CompanyFood Safety diagnostics, media, and sanitation,Animal Safety instruments, care products, and biosecurity,Genomics services for livestock and companion animals,
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables,
    IMMUCELL CORPORATIONUnited StatesPublic CompanyFirst Defense (core scours prevention),Tri-Shield First Defense,Dual-Force First Defense and related formulations,

    IDEXX

    IDEXX is a public company founded in 1983 and headquartered in the United States, employing 11,000 people.

    ELANCO

    Elanco is a public company founded in 1954 in the United States with 9,650 employees.

    MERCK & CO., INC.

    Merck & Co., Inc. is a public pharmaceutical company founded in 1891 and based in the United States, with 74,000 employees.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a public company founded in 1956 in the United States and employs 125,000 people.

    NEOGEN CORPORATION

    Neogen Corporation is a public company founded in 1981 in the United States with 2,974 employees.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States and employs 7,450 people.

    IMMUCELL CORPORATION

    ImmuCell Corporation is a public company founded in 1982 in the United States with 73 employees.

    Reasons to Buy this Report

    • Market Entry Strategy : Gain comprehensive insights into China's regulatory landscape, competitive dynamics, and market entry barriers. Identify optimal positioning strategies and partnership opportunities specific to Chinese veterinary biologics distribution channels.
    • Growth Opportunity Identification : Discover high-potential segments within livestock and companion animal markets. Understand emerging demand drivers and unmet needs to prioritize product development and commercialization efforts in China's expanding market.
    • Competitive Intelligence : Access detailed analysis of key market players, their market share, product portfolios, and strategic initiatives. Benchmark your offerings against competitors and identify differentiation opportunities in China's evolving landscape.
    • Investment Decision Support : Leverage accurate market sizing, growth projections, and trend analysis to support investment decisions and resource allocation. Make data-driven decisions on manufacturing facilities, R&D investments, and market expansion timelines in China.
    • Regulatory & Compliance Guidance : Understand China's evolving regulatory requirements for veterinary biologics approval, labeling, and distribution. Navigate compliance complexities and accelerate time-to-market for new products through informed regulatory strategy.

    Frequently asked questions

    What is the current size of China's veterinary biologics market?

    China's veterinary biologics market is valued at USD 25.02 million in 2025 and is projected to reach USD 34.06 million by 2030.

    What is the growth rate of China's veterinary biologics market?

    China's veterinary biologics market is growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2030.

    How does China's market growth compare to global trends?

    China's CAGR of 6.4% outpaces the global average of 5.2%, indicating that China is a high-growth market within the veterinary biologics sector.

    What factors are driving growth in China's veterinary biologics market?

    China's market growth is driven by government support for domestic vaccine manufacturing, rising pet ownership, strengthened biosecurity regulations, and expansion of livestock and aquaculture industries.

    What is the forecast for China's veterinary biologics market by 2030?

    China's veterinary biologics market is forecast to reach USD 34.06 million by 2030, representing a USD 9.04 million increase from the 2025 baseline.

    RESEARCH METHODOLOGY

    This study extensively used both primary and secondary sources. The research process examined various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, market dynamics, and strategies of major players.

    Secondary Research

    This research involved the use of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was employed to gather information for an extensive, technical, market-focused, and commercial analysis of the veterinary biologics market. It also helped obtain crucial details about key players, market classification, and segmentation based on industry trends at the most detailed levels, as well as significant developments related to market and technology perspectives. Additionally, a database of major industry leaders was created using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources from the supply side include project managers, sales managers, marketing managers, business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary biologics market. Primary sources from the demand side consist of professionals from veterinary hospitals and clinics, diagnostic labs, academic and research institutes, and pet owners.

    A breakdown of the primary respondents is provided below:

    Veterinary Biologics Market

    Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.

    Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

    Source: MarketsandMarkets Analysis

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The total size of the veterinary biologics market was determined through data triangulation from three different approaches, as outlined below. After each approach, a weighted average was calculated based on the level of assumptions used in each method.

    Veterinary Biologics Market

    Data Triangulation

    After defining the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown methods were used where applicable to complete the overall market analysis and determine accurate statistics for all segments and subsegments. The following figure illustrates the market validation, source structure, and data triangulation approach used in the market analysis process.

    Market Definition

    The veterinary biologics market includes all USDA-regulated biologic products, such as monoclonal antibodies, immunoglobulins, immunomodulators, and diagnostic kits, which are used for the prevention, diagnosis, or treatment of animal diseases. These products serve companion animals, livestock, and poultry across veterinary clinics, hospitals, diagnostic labs, and farm or herd settings, enabling veterinarians and animal health professionals to provide targeted immune-based interventions and rapid diagnostic testing. This allows infected animals to be identified quickly for faster treatment, containment, or herd management decisions.

    Stakeholders

    • Veterinary Biologics Manufacturers
    • Animal Healthcare Product Manufacturers
    • Veterinary Biologics Distributors and Wholesalers
    • Animal Welfare Associations
    • Veterinary Clinics and Care Centers
    • Research And Consulting Firms
    • Veterinary Research and Development Organizations
    • Contract Manufacturing Organizations
    • Venture Capitalists

    Report Objectives

    • To define, describe, and forecast the veterinary biologics market by product type, animal type, route of administration, application, end user, and region.
    • To provide detailed information about the key factors, such as drivers, restraints, opportunities, challenges, and industry trends, influencing the market growth
    • To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI on veterinary biologics market, case study analysis, adjacent market analysis, unmet needs/end user expectations in veterinary biologics market, and trends/disruption impacting customer business in the market
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To strategically analyze the market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market

     

    Get the Full Veterinary Biologics Market Report

    Full forecast, segment splits, and company analysis for all Veterinary Biologics Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status